By Chad Terhune LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

The U.K. is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy. Eli Lilly ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...